Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 16/20 | 0.43 |
| ▸ | JAK2 | O60674 | 6/20 | 0.43 |
| ▸ | TYK2 | P29597 | 3/20 | 0.43 |
| ▸ | JAK3 | P52333 | 3/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.38 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.38 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.33 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.33 |
| ▸ | PLK4 | O00444 | 1/20 | 0.33 |
| ▸ | STK25 | O00506 | 1/20 | 0.33 |
| ▸ | CIT | O14578 | 1/20 | 0.33 |
| ▸ | RIOK3 | O14730 | 1/20 | 0.33 |
| ▸ | IKBKB | O14920 | 1/20 | 0.33 |
| ▸ | CASK | O14936 | 1/20 | 0.33 |
| ▸ | GAK | O14976 | 1/20 | 0.33 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.33 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1504421 | 1.00 | JAK1 (0.43) | JAK1JAK2TYK2JAK3AURKA | |
| SCHEMBL9893749 | 1.00 | JAK1 (0.43) | JAK1JAK2TYK2JAK3AURKA | |
| SCHEMBL9893804 | 1.00 | JAK1 (0.43) | JAK1JAK2TYK2JAK3AURKA | |
| SCHEMBL9893905 | 1.00 | JAK1 (0.43) | JAK1JAK2TYK2JAK3AURKA | |
| SCHEMBL12833227 | 0.89 | JAK1 (0.41) | JAK1JAK2TYK2JAK3AURKA | |
| SCHEMBL9894879 | 0.86 | JAK1 (0.42) | JAK1JAK2TYK2JAK3AURKA | |
| SCHEMBL9894269 | 0.86 | JAK1 (0.42) | JAK1JAK2TYK2JAK3AURKA | |
| SCHEMBL9893865 | 0.86 | JAK1 (0.42) | JAK1JAK2TYK2JAK3AURKA | |
| SCHEMBL1504603 | 0.86 | JAK1 (0.42) | JAK1JAK2TYK2JAK3AURKA | |
| SCHEMBL9893734 | 0.86 | JAK1 (0.42) | JAK1JAK2TYK2JAK3AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | claimed |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | JAK1 2/4885JAK2 1/4885TYK2 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.